Clinical trials
Refractory Plasma Cell Myeloma clinical trials
Below are recruiting refractory plasma cell myeloma clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT07479979RecruitingPhase 1/Phase 2
Study of selinexor with carfilzomib, isatuximab and dexamethasone for relapsed/refractory multiple myeloma
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Madison, WisconsinAges 18 years+ - NCT07509086RecruitingPhase 2
Enhanced CAR-T therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
Changchun, JilinAges 18–80 - NCT07519187RecruitingEarly Phase 1
CAR-T Cell Therapy for Hard-to-Treat Blood Cancers
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
Chengdu, ChengduAges 18–75 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT06627751RecruitingPhase 2
Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Buffalo, New YorkAges 18 years+ - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT05521802RecruitingPhase 1/Phase 2
Testing a new CAR-T therapy for relapsed myeloma
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
TianjinAges 18 years+ - NCT06645678RecruitingPhase 1/Phase 2
Mezigdomide and Elranatamab for relapsed or hard-to-treat multiple myeloma
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
SingaporeAges 19 years+ - NCT07181941RecruitingPhase 1/Phase 2
Testing lower doses of linvoseltamab for multiple myeloma
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Seattle, WashingtonAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT05565807RecruitingPhase 1/Phase 2
Study drug for difficult myeloma after prior treatments
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06153251RecruitingPhase 1
Study of BMS-986453 for Relapsed or Refractory Multiple Myeloma
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT06574568RecruitingPhase 1
Study of YKST02 for relapsed or refractory multiple myeloma
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06832865RecruitingPhase 2
Elranatamab and isatuximab for relapsed multiple myeloma
This trial tests a combination of two drugs—elranatamab and isatuximab—for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this new combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+ - NCT07138209RecruitingPhase 3
Comparing QLS32015 to standard treatments for multiple myeloma
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+
Hear when a new Refractory Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory plasma cell myeloma?
- Yes. Clin2 currently lists 109 recruiting refractory plasma cell myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory plasma cell myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory plasma cell myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.